Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen M Whyte

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Journal of Affective Disorders|June 7, 2008
Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features?Taafoi S Kamara, Ellen M Whyte, Benoit H Mulsant, et al.
Psychological Medicine|March 26, 2021
Association between psychomotor disturbance and treatment outcome in psychotic depression: a STOP-PD II reportAlastair J Flint, Kathleen S Bingham, Nicholas H Neufeld, et al.
Psychiatry Research|May 27, 2022
Factor analysis of the CORE measure of psychomotor disturbance in psychotic depression: Findings from the STOP-PD II studyKathleen S Bingham, Nicholas H Neufeld, George S Alexopoulos, et al.
Journal of Affective Disorders|January 2, 2023
Residual or re-emergent impaired insight into delusions following remission is unrelated to later relapse during a randomized clinical trial of continuation pharmacotherapy for psychotic depression - The STOP-PD II StudyJianmeng Song, Benoit H Mulsant, Marcos Sanches, et al.
Journal of Psychiatric Research|December 19, 2022
Predictors of relapse of psychotic depression: Findings from the STOP-PD II randomized clinical trialAlastair J Flint, Kathleen S Bingham, George S Alexopoulos, et al.
Brain Injury|August 20, 2015
Pilot feasibility of an mHealth system for conducting ecological momentary assessment of mood-related symptoms following traumatic brain injuryShannon B Juengst, Kristin M Graham, I Wayan Pulantara, et al.
Molecular Psychiatry|March 20, 2024
Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic featuresHelena K Kim, Aristotle N Voineskos, Nicholas H Neufeld, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|December 3, 2020
Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II StudyAlastair J Flint, Anthony J Rothschild, Ellen M Whyte, et al.
Human Psychopharmacology|April 11, 2016
SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD studySimon J C Davies, Benoit H Mulsant, Alastair J Flint, et al.
Clinical Pharmacokinetics|May 15, 2015
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PDSimon J C Davies, Benoit H Mulsant, Alastair J Flint, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Journal of Affective Disorders|June 7, 2008
Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features?Taafoi S Kamara, Ellen M Whyte, Benoit H Mulsant, et al.
Psychological Medicine|March 26, 2021
Association between psychomotor disturbance and treatment outcome in psychotic depression: a STOP-PD II reportAlastair J Flint, Kathleen S Bingham, Nicholas H Neufeld, et al.
Psychiatry Research|May 27, 2022
Factor analysis of the CORE measure of psychomotor disturbance in psychotic depression: Findings from the STOP-PD II studyKathleen S Bingham, Nicholas H Neufeld, George S Alexopoulos, et al.
Journal of Affective Disorders|January 2, 2023
Residual or re-emergent impaired insight into delusions following remission is unrelated to later relapse during a randomized clinical trial of continuation pharmacotherapy for psychotic depression - The STOP-PD II StudyJianmeng Song, Benoit H Mulsant, Marcos Sanches, et al.
Journal of Psychiatric Research|December 19, 2022
Predictors of relapse of psychotic depression: Findings from the STOP-PD II randomized clinical trialAlastair J Flint, Kathleen S Bingham, George S Alexopoulos, et al.
Brain Injury|August 20, 2015
Pilot feasibility of an mHealth system for conducting ecological momentary assessment of mood-related symptoms following traumatic brain injuryShannon B Juengst, Kristin M Graham, I Wayan Pulantara, et al.
Molecular Psychiatry|March 20, 2024
Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic featuresHelena K Kim, Aristotle N Voineskos, Nicholas H Neufeld, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|December 3, 2020
Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II StudyAlastair J Flint, Anthony J Rothschild, Ellen M Whyte, et al.
Human Psychopharmacology|April 11, 2016
SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD studySimon J C Davies, Benoit H Mulsant, Alastair J Flint, et al.
Clinical Pharmacokinetics|May 15, 2015
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PDSimon J C Davies, Benoit H Mulsant, Alastair J Flint, et al.
Pageof 9